Skip to main content

Advertisement

SpringerLink
Log in

Roles of A20 in autoimmune diseases

  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

A20 (TNFAIP3), known to inhibit NF-κB function by deubiquitinating-specific NF-κB signaling molecules, has been found in many cell types of the immune system. Recent findings suggest that A20 is essential for the development and functional performance of dendritic cell, B cell, T cell and macrophage. A number of studies further demonstrate that these cells are crucial in the pathogenesis of autoimmune diseases, such as type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, ankylosing arthritis, Sjögren’s syndrome and rheumatoid arthritis. In this article, we focus on the recent advances on the roles of A20 in autoimmune diseases and discuss the therapeutic significance of these new findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem. 2009;284:8217–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004;430:694–9.

    Article  CAS  PubMed  Google Scholar 

  3. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, McNally E, Pickart C, Ma A. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004;5:1052–60.

    Article  CAS  PubMed  Google Scholar 

  4. Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE, Lee BL, Shiffin N, Advincula R, Malynn BA, Werts C, Ma A. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity. 2008;28:381–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Düwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P, Krappmann D. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol. 2009;182:7718–28.

    Article  PubMed  Google Scholar 

  6. Sisto M, Lisi S, Lofrumento DD, Ingravallo G, Maiorano E, D’Amore M. A failure of TNFAIP3 negative regulation maintains sustained NF-κB activation in Sjögren’s syndrome. Histochem Cell Biol. 2011;135:615–25.

    Article  CAS  PubMed  Google Scholar 

  7. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621–63.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang SQ, Kovalenko A, Cantarella G, Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity. 2000;12:301–11.

    Article  CAS  PubMed  Google Scholar 

  9. Liuwantara D, Elliot M, Smith MW, Yam AO, Walters SN, Marino E, McShea A, Grey ST. Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection. Diabetes. 2006;55:2491–501.

    Article  CAS  PubMed  Google Scholar 

  10. Cheng L, Zhang D, Jiang Y, Deng W, Wu Q, Jiang X, Chen B. Decreased A20 mRNA and protein expression in peripheral blood mononuclear cells in patients with type 2 diabetes and latent autoimmune diabetes in adults. Diabetes Res Clin Pract. 2014;106:611–6.

    Article  CAS  PubMed  Google Scholar 

  11. Kool M, van Loo G, Waelput W, De Prijck S, Muskens F, Sze M, van Praet J, Branco-Madeira F, Janssens S, Reizis B, Elewaut D, Beyaert R, Hammad H, Lambrecht BN. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity. 2011;35:82–96.

    Article  CAS  PubMed  Google Scholar 

  12. Billmann-Born S, Till A, Arlt A, Lipinski S, Sina C, Latiano A, Annese V, Häsler R, Kerick M, Manke T, Seegert D, Hanidu A, Schäfer H, van Heel D, Li J, Schreiber S, Rosenstiel P. Genome-wide expression profiling identifies an impairment of negative feedback signals in the Crohn’s disease-associated NOD2 variant L1007fsinsC. J Immunol. 2011;186:4027–38.

    Article  CAS  PubMed  Google Scholar 

  13. Arsenescu R, Bruno ME, Rogier EW, Stefka AT, McMahan AE, Wright TB, Nasser MS, de Villiers WJ, Kaetzel CS. Signature biomarkers in Crohn’s disease: toward a molecular classification. Mucosal Immunol. 2008;1:399–411.

    Article  CAS  PubMed  Google Scholar 

  14. Vereecke L, Sze M, Mc Guire C, Rogiers B, Chu Y, Schmidt-Supprian M, Pasparakis M, Beyaert R, van Loo G. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med. 2010;207:1513–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, Barrera J, Huang EJ, Hou B, Malynn BA, Reizis B, DeFranco A, Criswell LA, Nakamura MC, Ma A. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol. 2011;12:1184–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M, Geboes L, Louagie E, Mc Guire C, Vereecke L, Chu Y, Boon L, Staelens S, Matthys P, Lambrecht BN, Schmidt-Supprian M, Pasparakis M, Elewaut D, Beyaert R, van Loo G. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet. 2011;43:908–12.

    Article  CAS  PubMed  Google Scholar 

  17. Igarashi H, Yahagi A, Saika T, Hashimoto J, Tomita T, Yoshikawa H, Ishihara K. A pro-inflammatory role for A20 and ABIN family proteins in human fibroblast-like synoviocytes in rheumatoid arthritis. Immunol Lett. 2012;141:246–53.

    Article  CAS  PubMed  Google Scholar 

  18. Hah YS, Lee YR, Jun JS, Lim HS, Kim HO, Jeong YG, Hur GM, Lee SY, Chung MJ, Park JW, Lee SI, Park BH. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum. 2010;62:2313–21.

    Article  CAS  PubMed  Google Scholar 

  19. Warashina S, Nakamura T, Harashima H. A20 silencing by lipid envelope-type nanoparticles enhances the efficiency of lipopolysaccharide-activated dendritic cells. Biol Pharm Bull. 2011;34:1348–51.

    Article  CAS  PubMed  Google Scholar 

  20. Song XT, Evel-Kabler K, Shen L, Rollins L, Huang XF, Chen SY. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med. 2008;14:258–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Breckpot K, Aerts-Toegaert C, Heirman C, Peeters U, Beyaert R, Aerts JL, Thielemans K. Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J Immunol. 2009;182:860–70.

    Article  CAS  PubMed  Google Scholar 

  22. Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wójtowicz E, Soberon V, Schenten D, Mack B, Reutelshöfer M, Beyaert R, Amann K, van Loo G, Schmidt-Supprian M. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood. 2011;117:2227–36.

    Article  CAS  PubMed  Google Scholar 

  23. Hövelmeyer N, Reissig S, Xuan NT, Adams-Quack P, Lukas D, Nikolaev A, Schlüter D, Waisman A. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol. 2011;41:595–601.

    Article  PubMed  Google Scholar 

  24. Casola S, Rajewsky K. B cell recruitment and selection in mouse GALT germinal centers. Curr Top Microbiol Immunol. 2006;308:155–71.

    CAS  PubMed  Google Scholar 

  25. Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L, Barrera J, Lowell CA, Utz PJ, Malynn BA, Ma A. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity. 2010;33:181–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152–72.

    Article  CAS  PubMed  Google Scholar 

  27. Siracuse JJ, Fisher MD, da Silva CG, Peterson CR, Csizmadia E, Moll HP, Damrauer SM, Studer P, Choi LY, Essayagh S, Kaczmarek E, Maccariello ER, Lee A, Daniel S, Ferran C. A20-mediated modulation of inflammatory and immune responses in aortic allografts and development of transplant arteriosclerosis. Transplantation. 2012;93:373–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30:383–91.

    Article  CAS  PubMed  Google Scholar 

  29. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42.

    Article  CAS  PubMed  Google Scholar 

  30. Wang L, Hong B, Jiang X, Jones L, Chen SY, Huang XF. A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response. PLoS One. 2012;7:e48930.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Li D, Wang L, Fan Y, Song L, Guo C, Zhu F, Zhang L, Shi Y. Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Clin Immunol. 2012;32:1287–91.

    Article  CAS  PubMed  Google Scholar 

  32. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, Petri MA, Kamboh MI, Manzi S, Seldin MF, Gregersen PK, Behrens TW, Ma A, Kwok PY, Criswell LA. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet. 2008;40:1062–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Elsby LM, Orozco G, Denton J, Worthington J, Ray DW, Donn RP. Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:708–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6:9–20.

    Article  CAS  PubMed  Google Scholar 

  35. Vasilescu J, Zweitzig DR, Denis NJ, Smith JC, Ethier M, Haines DS, Figeys D. The proteomic reactor facilitates the analysis of affinity-purified proteins by mass spectrometry, application for identifying ubiquitinated proteins in human cells. J Proteome Res. 2007;6:298–305.

    Article  CAS  PubMed  Google Scholar 

  36. Gu Q, Tan M, Sun Y. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation. Cancer Res. 2007;67:3616–25.

    Article  CAS  PubMed  Google Scholar 

  37. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17–25.

    Article  CAS  PubMed  Google Scholar 

  38. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105–10.

    Article  CAS  PubMed  Google Scholar 

  39. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125–7.

    Article  CAS  PubMed  Google Scholar 

  40. Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, Bates JS, Hu Y, Kelly JA, Kaufman KM, Guthridge JM, Alarcón-Riquelme ME, BIOLUPUS and GENLES Networks, Anaya JM, Bae SC, Bang SY, Boackle SA, Brown EE, Petri MA, Gallant C, Ramsey-Goldman R, Reveille JD, Vila LM, Criswell LA, Edberg JC, Freedman BI, Gregersen PK, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Martin J, Merrill JT, Niewold TB, Park SY, Pons-Estel BA, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Harley JB, Moser KL, Webb CF, Humphrey MB, Montgomery CG, Gaffney PM. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011;43:253–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Bates JS, Lessard CJ, Leon JM, Nguyen T, Battiest LJ, Rodgers J, Kaufman KM, James JA, Gilkeson GS, Kelly JA, Humphrey MB, Harley JB, Gray-McGuire C, Moser KL, Gaffney PM. Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun. 2009;10:470–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wang S, Wen F, Wiley GB, Kinter MT, Gaffney PM. An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression. PLoS Genet. 2013;9:e1003750.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Suzhou High-tech Zone Center for Disease Prevention and Control, 35 Dengwei Road, Suzhou, 215011, Jiangsu, People’s Republic of China

      Min Zhang

    2. The Second People’s Hospital of Wuhu, 259 Jiuhua Central Road, Wuhu, 241000, Anhui, People’s Republic of China

      Ling-Long Peng

    3. Suzhou Municipal Center for Disease Prevention and Control, 72 Sanxiang Road, Suzhou, 215004, Jiangsu, People’s Republic of China

      Ying Wang, Jian-Shu Wang, Jiao Liu, Meng-Meng Liu, Jia Hu, Bin Song & Hai-Bing Yang

    Authors
    1. Min Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Ling-Long Peng
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Ying Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Jian-Shu Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Jiao Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Meng-Meng Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Jia Hu
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Bin Song
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Hai-Bing Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Hai-Bing Yang.

    Ethics declarations

    Conflict of interest

    The authors declare no other conflict of interest.

    Additional information

    Min Zhang and Ling-Long Peng have contributed equally to this work and should be considered as co-first authors.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Zhang, M., Peng, LL., Wang, Y. et al. Roles of A20 in autoimmune diseases. Immunol Res 64, 337–344 (2016). https://doi.org/10.1007/s12026-015-8677-6

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12026-015-8677-6

    Keywords

    Search

    Navigation